AbbVie Inc. Selling, General and Administrative Expense
AbbVie Inc. (ABBV) reported Selling, General and Administrative Expense of $3.63 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-03
- AbbVie Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $3.63B, a 11.65% increase year-over-year.
- AbbVie Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $3.58B, a 8.65% increase year-over-year.
- AbbVie Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $3.90B, a 1.04% increase year-over-year.
- AbbVie Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $3.57B, a 15.12% decline year-over-year.
- AbbVie Inc. selling, general and administrative expense for fiscal 2025 was $14.01B, a 5.03% decline from fiscal 2024.
- AbbVie Inc. selling, general and administrative expense for fiscal 2024 was $14.75B, a 14.61% increase from fiscal 2023.
- AbbVie Inc. selling, general and administrative expense for fiscal 2023 was $12.87B, a 15.65% decline from fiscal 2022.
- AbbVie Inc. selling, general and administrative expense for fiscal 2022 was $15.26B, a 23.57% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.63B 10-Q · filed 2026-08-03 | $7.21B 10-Q · filed 2026-08-03 | $11.11B derived: sum of 3 quarters · filed 2026-08-03 | $14.67B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | $3.58B 10-Q · filed 2026-05-08 | $7.47B derived: sum of 2 quarters · filed 2026-05-08 | $11.04B derived: sum of 3 quarters · filed 2026-05-08 | $14.29B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | $3.90B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $7.46B derived: sum of 2 quarters · filed 2026-02-20 | $10.72B derived: sum of 3 quarters · filed 2026-08-03 | $14.01B 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $3.57B 10-Q · filed 2025-11-04 | $6.82B derived: sum of 2 quarters · filed 2026-08-03 | $10.12B 10-Q · filed 2025-11-04 | $13.97B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $3.25B 10-Q · filed 2026-08-03 | $6.55B 10-Q · filed 2026-08-03 | $10.40B derived: sum of 3 quarters · filed 2026-08-03 | $14.61B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | $3.29B 10-Q · filed 2026-05-08 | $7.15B derived: sum of 2 quarters · filed 2026-05-08 | $11.35B derived: sum of 3 quarters · filed 2026-05-08 | $14.73B derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $3.85B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $8.06B derived: sum of 2 quarters · filed 2026-02-20 | $11.44B derived: sum of 3 quarters · filed 2026-02-20 | $14.75B 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $4.21B 10-Q · filed 2025-11-04 | $7.58B derived: sum of 2 quarters · filed 2025-11-04 | $10.90B 10-Q · filed 2025-11-04 | $14.09B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | $3.38B 10-Q · filed 2025-08-04 | $6.69B 10-Q · filed 2025-08-04 | $9.88B derived: sum of 3 quarters · filed 2026-02-20 | $13.26B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $3.31B 10-Q · filed 2025-05-09 | $6.51B derived: sum of 2 quarters · filed 2026-02-20 | $9.88B derived: sum of 3 quarters · filed 2026-02-20 | $13.15B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $3.19B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $6.57B derived: sum of 2 quarters · filed 2026-02-20 | $9.83B derived: sum of 3 quarters · filed 2026-02-20 | $12.87B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $3.37B 10-Q · filed 2024-11-04 | $6.64B derived: sum of 2 quarters · filed 2024-11-04 | $9.68B 10-Q · filed 2024-11-04 | $13.10B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $3.27B 10-Q · filed 2024-08-07 | $6.31B 10-Q · filed 2024-08-07 | $9.72B derived: sum of 3 quarters · filed 2025-02-14 | $13.03B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-03-31 | $3.04B 10-Q · filed 2024-05-03 | $6.46B derived: sum of 2 quarters · filed 2025-02-14 | $9.76B derived: sum of 3 quarters · filed 2025-02-14 | $15.17B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2022-12-31 | $3.42B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $6.72B derived: sum of 2 quarters · filed 2025-02-14 | $12.13B derived: sum of 3 quarters · filed 2025-02-14 | $15.26B 10-K · filed 2025-02-14 | ||||
| 2022-09-30 | $3.30B 10-Q · filed 2023-11-06 | $8.72B derived: sum of 2 quarters · filed 2023-11-06 | $11.84B 10-Q · filed 2023-11-06 | $15.10B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-06-30 | $5.41B 10-Q · filed 2023-08-07 | $8.54B 10-Q · filed 2023-08-07 | $11.80B derived: sum of 3 quarters · filed 2024-02-20 | $14.88B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | $3.13B 10-Q · filed 2023-05-05 | $6.39B derived: sum of 2 quarters · filed 2024-02-20 | $9.47B derived: sum of 3 quarters · filed 2024-02-20 | $12.63B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $3.26B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $6.34B derived: sum of 2 quarters · filed 2024-02-20 | $9.51B derived: sum of 3 quarters · filed 2024-02-20 | $12.35B 10-K · filed 2024-02-20 | ||||
| 2021-09-30 | $3.08B 10-Q · filed 2022-11-04 | $6.25B derived: sum of 2 quarters · filed 2022-11-04 | $9.09B 10-Q · filed 2022-11-04 | $12.32B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $3.16B 10-Q · filed 2022-08-04 | $6.01B 10-Q · filed 2022-08-04 | $9.24B derived: sum of 3 quarters · filed 2023-02-17 | $12.08B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $2.84B 10-Q · filed 2022-05-06 | $6.07B derived: sum of 2 quarters · filed 2023-02-17 | $8.92B derived: sum of 3 quarters · filed 2023-02-17 | $12.45B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | $3.23B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $6.08B derived: sum of 2 quarters · filed 2023-02-17 | $9.60B derived: sum of 3 quarters · filed 2023-02-17 | $11.30B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $2.85B 10-Q · filed 2021-11-02 | $6.37B derived: sum of 2 quarters · filed 2021-11-02 | $8.07B 10-Q · filed 2021-11-02 | $10.02B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | $3.53B 10-Q · filed 2021-08-02 | $5.22B 10-Q · filed 2021-08-02 | $7.17B derived: sum of 3 quarters · filed 2022-02-18 | $8.83B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $1.70B 10-Q · filed 2021-05-07 | $3.65B derived: sum of 2 quarters · filed 2022-02-18 | $5.30B derived: sum of 3 quarters · filed 2022-02-18 | $6.96B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2019-12-31 | $1.95B derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $3.61B derived: sum of 2 quarters · filed 2022-02-18 | $5.26B derived: sum of 3 quarters · filed 2022-02-18 | $6.94B 10-K · filed 2022-02-18 | ||||
| 2019-09-30 | $1.66B 10-Q · filed 2020-11-04 | $3.31B derived: sum of 2 quarters · filed 2020-11-04 | $4.99B 10-Q · filed 2020-11-04 | $6.92B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | $1.65B 10-Q · filed 2020-08-04 | $3.33B 10-Q · filed 2020-08-04 | $5.26B derived: sum of 3 quarters · filed 2021-02-19 | $7.18B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | $1.68B 10-Q · filed 2020-05-08 | $3.61B derived: sum of 2 quarters · filed 2021-02-19 | $5.53B derived: sum of 3 quarters · filed 2021-02-19 | $7.29B derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | $1.93B derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $3.85B derived: sum of 2 quarters · filed 2021-02-19 | $5.61B derived: sum of 3 quarters · filed 2021-02-19 | $7.40B 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $1.92B 10-Q · filed 2019-11-06 | $3.68B derived: sum of 2 quarters · filed 2019-11-06 | $5.47B 10-Q · filed 2019-11-06 | $7.43B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | $1.76B 10-Q · filed 2019-08-05 | $3.55B 10-Q · filed 2019-08-05 | $5.51B derived: sum of 3 quarters · filed 2020-02-21 | $6.96B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $1.79B 10-Q · filed 2019-05-03 | $3.75B derived: sum of 2 quarters · filed 2020-02-21 | $5.20B derived: sum of 3 quarters · filed 2020-02-21 | $6.71B derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | $1.96B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $3.41B derived: sum of 2 quarters · filed 2020-02-21 | $4.92B derived: sum of 3 quarters · filed 2020-02-21 | $6.29B 10-K · filed 2020-02-21 | $6.28B 10-K · filed 2018-02-16 | |||
| 2017-09-30 | $1.46B 10-Q · filed 2018-11-07 | $1.45B 10-Q · filed 2017-11-07 | $2.97B derived: sum of 2 quarters · filed 2018-11-07 | $4.34B 10-Q · filed 2018-11-07 | $4.32B 10-Q · filed 2017-11-07 | $6.02B derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-06-30 | $1.51B 10-Q · filed 2018-08-07 | $1.50B 10-Q · filed 2017-08-07 | $2.88B 10-Q · filed 2018-08-07 | $2.87B 10-Q · filed 2017-08-07 | $4.56B derived: sum of 3 quarters · filed 2019-02-27 | $5.94B derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2017-03-31 | $1.37B 10-Q · filed 2018-05-04 | $1.37B 10-Q · filed 2017-05-05 | $3.05B derived: sum of 2 quarters · filed 2019-02-27 | $4.43B derived: sum of 3 quarters · filed 2019-02-27 | $5.90B derived: sum of 4 quarters · filed 2019-02-27 | |||
| 2016-12-31 | $1.68B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $3.06B derived: sum of 2 quarters · filed 2019-02-27 | $4.53B derived: sum of 3 quarters · filed 2019-02-27 | $5.88B 10-K · filed 2019-02-27 | $5.86B 10-K · filed 2017-02-17 | |||
| 2016-09-30 | $1.38B 10-Q · filed 2017-11-07 | $2.85B derived: sum of 2 quarters · filed 2017-11-07 | $4.20B 10-Q · filed 2017-11-07 | $5.94B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $1.47B 10-Q · filed 2017-08-07 | $2.82B 10-Q · filed 2017-08-07 | $4.56B derived: sum of 3 quarters · filed 2018-02-16 | $6.03B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $1.35B 10-Q · filed 2017-05-05 | $3.09B derived: sum of 2 quarters · filed 2018-02-16 | $4.57B derived: sum of 3 quarters · filed 2018-02-16 | $6.27B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $1.74B derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $3.21B derived: sum of 2 quarters · filed 2018-02-16 | $4.91B derived: sum of 3 quarters · filed 2018-02-16 | $6.39B 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $1.47B 10-Q · filed 2016-11-07 | $3.18B derived: sum of 2 quarters · filed 2016-11-07 | $4.65B 10-Q · filed 2016-11-07 | $7.99B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $1.70B 10-Q · filed 2016-08-05 | $3.18B 10-Q · filed 2016-08-05 | $6.52B derived: sum of 3 quarters · filed 2017-02-17 | $8.11B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $1.47B 10-Q · filed 2016-05-06 | $4.81B derived: sum of 2 quarters · filed 2017-02-17 | $6.41B derived: sum of 3 quarters · filed 2017-02-17 | $7.86B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | $3.34B derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $4.94B derived: sum of 2 quarters · filed 2017-02-17 | $6.38B derived: sum of 3 quarters · filed 2017-02-17 | $7.72B 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $1.59B 10-Q · filed 2015-11-06 | $3.04B derived: sum of 2 quarters · filed 2015-11-06 | $4.38B 10-Q · filed 2015-11-06 | $5.83B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $1.45B 10-Q · filed 2015-08-07 | $2.79B 10-Q · filed 2015-08-07 | $4.24B derived: sum of 3 quarters · filed 2016-02-19 | $5.50B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | $1.34B 10-Q · filed 2015-05-08 | $2.79B derived: sum of 2 quarters · filed 2016-02-19 | $4.05B derived: sum of 3 quarters · filed 2016-02-19 | $5.46B derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | $1.45B derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $2.71B derived: sum of 2 quarters · filed 2016-02-19 | $4.12B derived: sum of 3 quarters · filed 2016-02-19 | $5.35B 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $1.26B 10-Q · filed 2014-11-07 | $2.67B derived: sum of 2 quarters · filed 2014-11-07 | $3.90B 10-Q · filed 2014-11-07 | $5.32B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-06-30 | $1.41B 10-Q · filed 2014-08-07 | $2.64B 10-Q · filed 2014-08-07 | $4.05B derived: sum of 3 quarters · filed 2015-02-20 | $5.14B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-03-31 | $1.24B 10-Q · filed 2014-05-09 | $2.65B derived: sum of 2 quarters · filed 2015-02-20 | $3.73B derived: sum of 3 quarters · filed 2015-02-20 | $4.98B derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2012-12-31 | $1.41B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $2.50B derived: sum of 2 quarters · filed 2015-02-20 | $3.74B derived: sum of 3 quarters · filed 2015-02-20 | $4.99B 10-K · filed 2015-02-20 | ||||
| 2012-09-30 | $1.08B 10-Q · filed 2013-11-12 | $2.33B derived: sum of 2 quarters · filed 2013-11-12 | $3.58B 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | $1.25B 10-Q · filed 2013-08-09 | $2.49B 10-Q · filed 2013-08-09 | ||||||
| 2012-03-31 | $1.25B 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $5.89B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |